Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Comparable Genital Tract Infection, Pathology, and Immunity in Rhesus Macaques Inoculated with Wild-Type or Plasmid-Deficient Chlamydia trachomatis Serovar D.

Qu Y, Frazer LC, O'Connell CM, Tarantal AF, Andrews CW Jr, O'Connor SL, Russell AN, Sullivan JE, Poston TB, Vallejo AN, Darville T.

Infect Immun. 2015 Oct;83(10):4056-67. doi: 10.1128/IAI.00841-15. Epub 2015 Jul 27.

2.

Steroids alone or as adjunctive therapy with doxycycline fail to improve oviduct damage in mice infected with Chlamydia muridarum.

Corr TE, Sullivan J, Frazer LC, Andrews CW Jr, O'Connell CM, Darville T.

Clin Vaccine Immunol. 2014 Jun;21(6):824-30. doi: 10.1128/CVI.00006-14. Epub 2014 Apr 2.

3.

IL-23 induces IL-22 and IL-17 production in response to Chlamydia muridarum genital tract infection, but the absence of these cytokines does not influence disease pathogenesis.

Frazer LC, Scurlock AM, Zurenski MA, Riley MM, Mintus M, Pociask DA, Sullivan JE, Andrews CW Jr, Darville T.

Am J Reprod Immunol. 2013 Dec;70(6):472-84. doi: 10.1111/aji.12171.

4.

The recall response induced by genital challenge with Chlamydia muridarum protects the oviduct from pathology but not from reinfection.

Riley MM, Zurenski MA, Frazer LC, O'Connell CM, Andrews CW Jr, Mintus M, Darville T.

Infect Immun. 2012 Jun;80(6):2194-203. doi: 10.1128/IAI.00169-12. Epub 2012 Mar 19.

5.

Plasmid-cured Chlamydia caviae activates TLR2-dependent signaling and retains virulence in the guinea pig model of genital tract infection.

Frazer LC, Darville T, Chandra-Kuntal K, Andrews CW Jr, Zurenski M, Mintus M, AbdelRahman YM, Belland RJ, Ingalls RR, O'Connell CM.

PLoS One. 2012;7(1):e30747. doi: 10.1371/journal.pone.0030747. Epub 2012 Jan 24.

6.

Enhanced neutrophil longevity and recruitment contribute to the severity of oviduct pathology during Chlamydia muridarum infection.

Frazer LC, O'Connell CM, Andrews CW Jr, Zurenski MA, Darville T.

Infect Immun. 2011 Oct;79(10):4029-41. doi: 10.1128/IAI.05535-11. Epub 2011 Aug 8.

7.

Interleukin-17 contributes to generation of Th1 immunity and neutrophil recruitment during Chlamydia muridarum genital tract infection but is not required for macrophage influx or normal resolution of infection.

Scurlock AM, Frazer LC, Andrews CW Jr, O'Connell CM, Foote IP, Bailey SL, Chandra-Kuntal K, Kolls JK, Darville T.

Infect Immun. 2011 Mar;79(3):1349-62. doi: 10.1128/IAI.00984-10. Epub 2010 Dec 13.

8.
9.

Infectivity acts as in vivo selection for maintenance of the chlamydial cryptic plasmid.

Russell M, Darville T, Chandra-Kuntal K, Smith B, Andrews CW Jr, O'Connell CM.

Infect Immun. 2011 Jan;79(1):98-107. doi: 10.1128/IAI.01105-10. Epub 2010 Oct 25.

10.

Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.

Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4587-92. doi: 10.1016/j.bmcl.2010.06.009. Epub 2010 Jun 8.

PMID:
20594842
11.

Critical role for interleukin-1beta (IL-1beta) during Chlamydia muridarum genital infection and bacterial replication-independent secretion of IL-1beta in mouse macrophages.

Prantner D, Darville T, Sikes JD, Andrews CW Jr, Brade H, Rank RG, Nagarajan UM.

Infect Immun. 2009 Dec;77(12):5334-46. doi: 10.1128/IAI.00883-09. Epub 2009 Oct 5.

12.

Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

Emmitte KA, Adjabeng GM, Andrews CW, Alberti JG, Bambal R, Chamberlain SD, Davis-Ward RG, Dickson HD, Hassler DF, Hornberger KR, Jackson JR, Kuntz KW, Lansing TJ, Mook RA Jr, Nailor KE, Pobanz MA, Smith SC, Sung CM, Cheung M.

Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7. doi: 10.1016/j.bmcl.2009.01.094. Epub 2009 Jan 31. Erratum in: Bioorg Med Chem Lett. 2009 May 1;19(9):2604. Adjebang, George M [corrected to Adjabeng, George M].

PMID:
19237286
13.

Discovery of thiophene inhibitors of polo-like kinase.

Emmitte KA, Andrews CW, Badiang JG, Davis-Ward RG, Dickson HD, Drewry DH, Emerson HK, Epperly AH, Hassler DF, Knick VB, Kuntz KW, Lansing TJ, Linn JA, Mook RA Jr, Nailor KE, Salovich JM, Spehar GM, Cheung M.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. doi: 10.1016/j.bmcl.2008.11.041. Epub 2008 Nov 18.

PMID:
19097784
14.

Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.

Cheung M, Kuntz KW, Pobanz M, Salovich JM, Wilson BJ, Andrews CW 3rd, Shewchuk LM, Epperly AH, Hassler DF, Leesnitzer MA, Smith JL, Smith GK, Lansing TJ, Mook RA Jr.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6214-7. doi: 10.1016/j.bmcl.2008.09.100. Epub 2008 Oct 2.

PMID:
18929484
15.

Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.

Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, Boone L, Chan JH, Stammers DK.

J Med Chem. 2008 Aug 28;51(16):5000-8. doi: 10.1021/jm8004493. Epub 2008 Jul 30.

PMID:
18665583
16.

Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model.

Nagarajan UM, Prantner D, Sikes JD, Andrews CW Jr, Goodwin AM, Nagarajan S, Darville T.

Infect Immun. 2008 Oct;76(10):4642-8. doi: 10.1128/IAI.00629-08. Epub 2008 Jul 28.

17.

Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease.

O'Connell CM, Ingalls RR, Andrews CW Jr, Scurlock AM, Darville T.

J Immunol. 2007 Sep 15;179(6):4027-34.

18.

Effect of the purinergic receptor P2X7 on Chlamydia infection in cervical epithelial cells and vaginally infected mice.

Darville T, Welter-Stahl L, Cruz C, Sater AA, Andrews CW Jr, Ojcius DM.

J Immunol. 2007 Sep 15;179(6):3707-14.

19.

Lack of an effect of antibiotic treatment on prolonged detection of chlamydial DNA in murine genital tract infection.

Reeves DM, Nagarajan U, O'Connell C, Andrews CW Jr, Darville T.

Antimicrob Agents Chemother. 2007 Jul;51(7):2646-8. Epub 2007 May 14.

20.

A critical assessment of docking programs and scoring functions.

Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS.

J Med Chem. 2006 Oct 5;49(20):5912-31.

PMID:
17004707
21.

Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

Miller JF, Andrews CW, Brieger M, Furfine ES, Hale MR, Hanlon MH, Hazen RJ, Kaldor I, McLean EW, Reynolds D, Sammond DM, Spaltenstein A, Tung R, Turner EM, Xu RX, Sherrill RG.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1788-94. Epub 2006 Feb 3.

PMID:
16458505
22.

Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.

Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR.

J Med Chem. 2006 Jan 26;49(2):727-39.

PMID:
16420058
23.

Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis.

Haskell H, Andrews CW Jr, Reddy SI, Dendrinos K, Farraye FA, Stucchi AF, Becker JM, Odze RD.

Am J Surg Pathol. 2005 Nov;29(11):1472-81.

PMID:
16224214
24.

Ampullary stenosis with biliary obstruction in duodenal Crohn's disease: a case report and review of the literature.

Yung K, Oviedo J, Farraye FA, Becker JM, Andrews CW Jr, Lichtenstein D.

Dig Dis Sci. 2005 Jun;50(6):1118-21. Review. No abstract available.

PMID:
15986865
25.

Pathologic quiz case: a 38-year-old woman with a flesh-colored forehead nodule. Pleomorphic fibroma.

Manucha V, Andrews CW Jr.

Arch Pathol Lab Med. 2005 Jan;129(1):e21-2. No abstract available.

PMID:
15628922
26.

Gastroduodenal Crohn's disease.

Fix OK, Soto JA, Andrews CW, Farraye FA.

Gastrointest Endosc. 2004 Dec;60(6):985. No abstract available.

PMID:
15605018
27.

Optimization of pyrrolidinone based HIV protease inhibitors.

Sherrill RG, Andrews CW, Bock WJ, Davis-Ward RG, Furfine ES, Hazen RJ, Rutkowske RD, Spaltenstein A, Wright LL.

Bioorg Med Chem Lett. 2005 Jan 3;15(1):81-4.

PMID:
15582415
28.

Protection against Chlamydia trachomatis infection in vitro and modulation of inflammatory response in vivo by membrane-bound glycosaminoglycans.

Darville T, Yedgar S, Krimsky M, Andrews CW Jr, Jungas T, Ojcius DM.

Microbes Infect. 2004 Apr;6(4):369-76.

PMID:
15050964
29.

Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Chan JH, Freeman GA, Tidwell JH, Romines KR, Schaller LT, Cowan JR, Gonzales SS, Lowell GS, Andrews CW 3rd, Reynolds DJ, St Clair M, Hazen RJ, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Koszalka GW, Boone LR.

J Med Chem. 2004 Feb 26;47(5):1175-82.

PMID:
14971897
30.

Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection.

Darville T, O'Neill JM, Andrews CW Jr, Nagarajan UM, Stahl L, Ojcius DM.

J Immunol. 2003 Dec 1;171(11):6187-97.

31.

Role of proapoptotic BAX in propagation of Chlamydia muridarum (the mouse pneumonitis strain of Chlamydia trachomatis) and the host inflammatory response.

Perfettini JL, Ojcius DM, Andrews CW Jr, Korsmeyer SJ, Rank RG, Darville T.

J Biol Chem. 2003 Mar 14;278(11):9496-502. Epub 2002 Dec 31.

32.

Mouse strain-dependent chemokine regulation of the genital tract T helper cell type 1 immune response.

Darville T, Andrews CW Jr, Sikes JD, Fraley PL, Braswell L, Rank RG.

Infect Immun. 2001 Dec;69(12):7419-24.

33.

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.

Chan JH, Hong JS, Hunter RN 3rd, Orr GF, Cowan JR, Sherman DB, Sparks SM, Reitter BE, Andrews CW 3rd, Hazen RJ, St Clair M, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Ott RJ, Ren J, Hopkins A, Stuart DI, Stammers DK.

J Med Chem. 2001 Jun 7;44(12):1866-82.

PMID:
11384233
34.

Early local cytokine profiles in strains of mice with different outcomes from chlamydial genital tract infection.

Darville T, Andrews CW Jr, Sikes JD, Fraley PL, Rank RG.

Infect Immun. 2001 Jun;69(6):3556-61.

35.
36.
37.

Conformation and local environment of nucleotides bound to HIV type 1 reverse transcriptase (HIV-1 RT) in the ground state.

Painter GR, Andrews CW, Furman PA.

Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):13-29.

PMID:
10772700
38.

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD.

Hepatology. 1998 Jun;27(6):1670-7.

PMID:
9620341
39.

Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response.

Darville T, Andrews CW Jr, Laffoon KK, Shymasani W, Kishen LR, Rank RG.

Infect Immun. 1997 Aug;65(8):3065-73.

40.

Molecular diversity in chemical databases: comparison of medicinal chemistry knowledge bases and databases of commercially available compounds.

Cummins DJ, Andrews CW, Bentley JA, Cory M.

J Chem Inf Comput Sci. 1996 Jul-Aug;36(4):750-63.

PMID:
8768767
41.

Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma.

Jessup JM, Lavin PT, Andrews CW Jr, Loda M, Mercurio A, Minsky BD, Mies C, Cukor B, Bleday R, Steele G Jr.

Dis Colon Rectum. 1995 Dec;38(12):1257-64.

PMID:
7497836
42.

4-(Heteroarylthio)-2-biphenylyltetrazoles as nonpeptide angiotensin II antagonists.

Norman MH, Smith HD, Andrews CW, Tang FL, Cowan CL, Steffen RP.

J Med Chem. 1995 Nov 10;38(23):4670-8.

PMID:
7473594
43.

Prospective evaluation of early morphological changes in pelvic ileal pouches.

Apel R, Cohen Z, Andrews CW Jr, McLeod R, Steinhart H, Odze RD.

Gastroenterology. 1994 Aug;107(2):435-43.

PMID:
8039620
44.

Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon.

Andrews CW Jr, Jessup JM, Goldman H, Hayes DF, Kufe DW, O'Hara CJ, Steele GD Jr.

Cancer. 1993 Dec 1;72(11):3185-90.

PMID:
7694786
45.

Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma.

Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A, Mercurio AM.

Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3466-70.

46.

A comparison of the conformations of the 5'-triphosphates of zidovudine (AZT) and thymidine bound to HIV-1 reverse transcriptase.

Painter GR, Aulabaugh AE, Andrews CW.

Biochem Biophys Res Commun. 1993 Mar 31;191(3):1166-71.

PMID:
7682061
47.

Endoscopic surveillance of Barrett's esophagus. Does it help?

Streitz JM Jr, Andrews CW Jr, Ellis FH Jr.

J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8.

PMID:
8445916
48.

Sucrase-isomaltase expression in chronic ulcerative colitis and dysplasia.

Andrews CW Jr, O'Hara CJ, Goldman H, Mercurio AM, Silverman ML, Steele GD Jr.

Hum Pathol. 1992 Jul;23(7):774-9.

PMID:
1612577
49.
50.

DNA intercalation and inhibition of topoisomerase II. Structure-activity relationships for a series of amiloride analogs.

Besterman JM, Elwell LP, Cragoe EJ Jr, Andrews CW, Cory M.

J Biol Chem. 1989 Feb 5;264(4):2324-30.

Supplemental Content

Loading ...
Support Center